TWI589228B - 降低膽固醇含量之奶產品 - Google Patents
降低膽固醇含量之奶產品 Download PDFInfo
- Publication number
- TWI589228B TWI589228B TW099112408A TW99112408A TWI589228B TW I589228 B TWI589228 B TW I589228B TW 099112408 A TW099112408 A TW 099112408A TW 99112408 A TW99112408 A TW 99112408A TW I589228 B TWI589228 B TW I589228B
- Authority
- TW
- Taiwan
- Prior art keywords
- milk
- cholesterol
- fat
- content
- fatty acid
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims description 156
- 235000013336 milk Nutrition 0.000 title claims description 84
- 239000008267 milk Substances 0.000 title claims description 84
- 210000004080 milk Anatomy 0.000 title claims description 84
- 235000012000 cholesterol Nutrition 0.000 title claims description 73
- 235000021243 milk fat Nutrition 0.000 claims description 68
- 239000003925 fat Substances 0.000 claims description 55
- 235000019197 fats Nutrition 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 43
- 210000004369 blood Anatomy 0.000 claims description 40
- 239000008280 blood Substances 0.000 claims description 40
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 23
- 241000124008 Mammalia Species 0.000 claims description 22
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 19
- 235000013365 dairy product Nutrition 0.000 claims description 14
- 229960004488 linolenic acid Drugs 0.000 claims description 14
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 13
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 12
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 12
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 12
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 12
- 201000001320 Atherosclerosis Diseases 0.000 claims description 11
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 150000004665 fatty acids Chemical class 0.000 claims description 10
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 10
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 9
- 235000013351 cheese Nutrition 0.000 claims description 8
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 8
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 8
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 5
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 5
- 150000003626 triacylglycerols Chemical class 0.000 claims description 5
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 235000015243 ice cream Nutrition 0.000 claims description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 4
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 3
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 235000015140 cultured milk Nutrition 0.000 claims description 2
- 235000019541 flavored milk drink Nutrition 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 claims description 2
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 235000021003 saturated fats Nutrition 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 235000021084 monounsaturated fats Nutrition 0.000 claims 1
- 239000000047 product Substances 0.000 description 51
- 235000013305 food Nutrition 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 241000282412 Homo Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 13
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 12
- 241000282849 Ruminantia Species 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940090949 docosahexaenoic acid Drugs 0.000 description 6
- 239000008256 whipped cream Substances 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000001497 healthy food Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 238000012754 cardiac puncture Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 235000020124 milk-based beverage Nutrition 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000019246 Developmental coordination disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000019896 Motor Skills disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- QYIXCDOBOSTCEI-NWKZBHTNSA-N coprostanol Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-NWKZBHTNSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 125000005481 linolenic acid group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- -1 phosphate ester Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C13/00—Cream; Cream preparations; Making thereof
- A23C13/12—Cream preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C15/00—Butter; Butter preparations; Making thereof
- A23C15/12—Butter preparations
- A23C15/14—Butter powder; Butter oil, i.e. melted butter, e.g. ghee ; Anhydrous butter
- A23C15/145—Removal of steroids, e.g. cholesterol or free acids; Fractionation of anhydrous milkfat by extraction with solvents other than solvent crystallisation or with supercritical gases or by distillation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C7/00—Other dairy technology
- A23C7/04—Removing unwanted substances other than lactose or milk proteins from milk
- A23C7/043—Removing unwanted substances other than lactose or milk proteins from milk using chemicals in liquid or solid state, e.g. flocculating, adsorbing or extracting agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Dairy Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Feed For Specific Animals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Confectionery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本發明係應用於哺乳動物(特別是人類)疾病之治療及/或防治之領域,係有關於一種包括含有此奶產品(乳汁或其製品)組成之飼料或食品者,該奶類產品係取自反芻動物,最好為來自牛隻之奶產品(乳汁或其製品),更好為來自乳牛之奶產品(乳汁或其製品),係為降低膽固醇含量之奶產品。
已開發國家傾向於消耗具有富三酸甘油酯或脂肪(例如,淨重22%左右之攝取量)及富膽固醇之食物。
酯類混亂(Lipid disorder)係用於定義哺乳動物高血液膽固醇及三酸甘油酯比率之醫學名詞,係有關於增加心血管疾病特別是動脈硬化及其他哺乳動物,尤其人類之心臟疾病者。
乳汁中含有3至8%左右的脂肪(重量:重量),其中主要為飽和脂肪酸。
脂肪(三酸甘油酯)是使乳汁具有乳香,及其「技術上的」特性的主要來源,特別是以乳汁製造之產品(奶產品),諸如塗抹料、乳酪、鮮奶油等等。
乳汁製造之產品的脂肪含量可在淨重3至100%左右(總重介於10%與80%左右之間)。譬如,乳酪跟奶油含有45%(淨重)左右及80%左右的脂肪(總重,或淨重高達98%)。
不飽和脂肪酸,特別是ω 3多元不飽和脂肪酸,如α亞麻酸(ALA),二十碳五烯酸(EPA)及/或十二碳六烯酸(DHA),係有益健康,其特性係顯現在添加多元不飽和
脂肪之健康食品之組成,食物補充劑或營養補給品。
這些特殊的脂肪酸可以脂肪(三酸甘油酯)、磷酯的形式呈現,或者帶有脂肪酸之變化形式者,諸如脂蛋白。
然而,(反芻動物)之乳汁係缺乏(多元)不飽和脂肪酸。通常,一種含添加物之奶產品(譬如添加植物油)不能標示為奶產品。
再者,乳脂肪含有膽固醇(每100g脂肪含300mg左右)。然而,必須將膽固醇食物之攝取量限制在每日最多300mg。所以,要增進乳脂肪的營養價值,將涉及降低其膽固醇之含量。
已知膽固醇及飽和脂肪酸皆有害(人體)健康,尤其相關於心血管疾病及某些癌症。
因此,含有豐富乳脂肪之全脂奶、乳脂肪及奶產品(諸如奶油、鮮奶油、乳酪…)及含有此類奶產品之食品或飼料組成,由於其高含量之飽和脂肪酸及膽固醇,造成相關研究中不良營養之印象。
目前,工業界可藉由物理方法從乳脂肪萃取膽固醇,諸如分子覆被(molecular encapsulation),藉由接觸環糊精(EP-387708 B1)或蒸汽蒸餾等方法。使用這些方法初步可萃取出至少75%的膽固醇。
或者,發展出降低乳汁膽固醇含量,或者其生體利用率(bio-availability)的多種方法。
譬如,如美國專利US6485931B2所述,將奶類膽固醇
轉化成具有低度之生體利用率之糞醇(coprostanol)。
如世界專利申請案WO 2004 052 122所述之藉由改變其組成之降低動物性脂肪膽固醇含量之方法。
歐洲專利EP 1585508 B1係有關於使用鞘酯(sphingolipids)於食品或藥品製造,以降低離子體及/或乳漿狀態之膽固醇及三酸甘油酯,及使用鞘酯藉由降低離子體及/或乳漿狀態之膽固醇及三酸甘油酯應用於治療或預防人類之心血管疾病。
如歐洲專利EP 0615 690所述者,係使用油脂萃取奶類膽固醇。
如美國專利US 5 175 015所述者,係將撇去浮油的奶混合以植物油。
本發明之目的在於提供一種食品或飼料成份或一種食品或飼料之組成,且不具已知技藝之缺點,特別是一種可預防或治療(或改善)哺乳動物(包括人類)心血管疾病及/或相關疾病,如癌症,以增進其健康,尤其是人類。
本發明之目的在於提供一種可應用於健康食品或飼料(組成),或一種營養補給品成份或組成,亦可以以下奶產品之一般奶產品或飼料或食品組成之形式存在(乳汁及奶類飲品、塗抹料,特別是奶油、鮮奶油、乳酪等),或取自上述奶產品製造者(冰淇淋、糖果糕點食品等)。
本發明亦有關於使反芻動物之乳汁(乳脂肪),最好是
牛乳(乳脂肪)具有療效。
本發明之奶產品(乳汁或其製品),特別是乳脂肪,係具有低膽固醇含量,理想含量在10mg/100g脂肪左右到150mg/100g脂肪左右之間,較佳在30mg/100g脂肪左右到150mg/100g脂肪左右之間,最佳含量在30mg/100g脂肪左右到90mg/100g脂肪左右之間。
本發明之奶產品(乳汁或其製品),特別是乳脂肪,最好取自反芻動物,更好取自牛隻。
本發明之奶產品(乳汁或其製品),特別是乳脂肪,飽和脂肪含量最好為60%到70%左右(飽和脂肪酸重量:總重)。
本發明之奶產品係一種乳汁,其蛋白質(其中含80%之酪蛋白)含量介於3%左右到4%左右(重量:重量),脂肪含量介於3%左右到6%左右(重量:重量),碳水化合物含量介於4%左右到5%左右(重量:重量),礦物質含量介於0.6%左右到1%左右(重量:重量),主要為鈣、鉀、氯化物及…(例如,奶製品總重之%係為100%)。
或者,本發明之奶產品係一種在乳脂肪中添加物質之奶產品,諸如塗抹料,最好是奶油、奶類飲品、鮮奶油或乳酪之產品。本發明係有關於一種健康食品或飼料組成,其中包括本發明之奶產品或乳脂肪,或取自本發明之奶產品或乳脂肪製造者,如冰淇淋、糖果糕餅。
使用「左右」之情況,係誤差在正或負10%之間。譬如,「4%左右」,意謂著實際數值係介於3.6%與4.4%之間。
本發明取自反芻動物乳汁之反芻動物奶產品(乳汁、乳製品或脂肪),可單獨使用(以乳汁、鮮奶油或無水乳脂肪之
形式),或為萃取之產品(像奶油之塗抹料,飲品或乳酪),或為健康食品組成之補充成份或有效成份,或在健康食品組成與其他一般成份結合,或在營養補給品組成中及/或在具有療效之組成中。
包含本發明奶產品,特別是乳脂肪之藥品(具有療效之組成)及/或營養補給品,係提供一種食品組成,最好是塗抹料、更好為介於10%到50%左右間(40%左右較佳)脂肪(重量:重量)之奶油,其膽固醇含量係介於10mg/100g左右與150mg/100g脂肪左右之間,介於30mg/100g與150mg/100g脂肪左右之間較佳,介於30mg/100g與90mg/100g脂肪左右之間更佳。
其優越性在於當攝取本發明之奶製品時,特別是乳脂肪,將在哺乳動物(包括人類)血液中增加(長鍊)多元不飽和脂肪酸成份(諸如花生四烯酸(Arachidonic acid)、二十碳五烯酸(Eicosapentaenoic acid)及十二碳六烯酸(Docosahexaenoic acid))。
更優越之處在於當攝取本發明之奶製品時,特別是乳脂肪,可進一步在哺乳動物(包括人類)血液中增加長鍊多元不飽和脂肪酸成份ω 3脂肪酸成份。
長鏈ω 3脂肪酸,意謂二十碳五烯酸(EPA)及十二碳六烯酸(DHA)。
當攝取本發明之奶製品時,特別是乳脂肪,可進一步減少在哺乳動物(包括人類)血液中之三酸甘油脂含量(比較未降低膽固醇含量之反芻動物乳脂肪(其膽固醇含量為280mg/100g脂肪))。
當攝取本發明之奶製品時,特別是乳脂肪,可在哺乳動物(包括人類)血液中增加至少15%左右(至少30%左右較佳,至少50%左右更佳)之HDL膽固醇含量,增加10%左右以下之非HDL血膽固醇含量較佳,20%以下更佳。
因此,當攝取本發明之奶製品時,特別是乳脂肪,也降低哺乳動物血液(包括人類)之動脈粥狀硬化率到至少10%左右,至少20%左右較佳,至少30%左右更佳。
本發明進一步係有關於一種添加奶產品,特別是乳脂肪之食物(藥用及/或營養食品)組成,該食品係具有低膽固醇含量,並含有介於12%左右到90%左右之間(22%左右到50%左右之間較佳,35%左右到45%左右之間更佳)(淨重之重量比)的脂肪,以降低哺乳動物(包括人類)血液中之總膽固醇含量(比較未降低膽固醇含量之反芻動物乳脂肪其膽固醇含量為280mg/100g脂肪左右)。
本發明之食品(藥用及/或營養食品)係選自以下表列之奶製品,最好為塗抹料組成奶油及可塗抹之奶油,冰淇淋、鮮奶油、乳酪、發酵奶、加味奶及奶精。
另一個組成結構的觀點,其中乳脂肪係由添加降低膽固醇之乳脂肪及/或組成結構取代為降低膽固醇之乳脂肪,最好本發明之該降低膽固醇之乳脂肪可作為藥品使用。
作為藥用者之組成結構最好含有10%左右到22%左右的脂肪總重(重量:重量;淨重),包括乳脂肪(降低膽固醇含量者)及降低膽固醇含量之脂肪(含有介於10mg/100g左右到150mg/100g左右脂肪總重之間),介於30mg/100g左右到150mg/100g左右脂肪總重之間較好,介於30mg/100g左
右到90mg/100g左右脂肪總重之間更好。
本發明之奶製品(或包含本發明之奶產品之組成結構),特別是乳脂肪,係應用於治療及/或預防神經性疾病,特別是來自憂鬱症候群(包括產後憂鬱症)、阿茲海默症、行為異常,諸如注意力不足過動症(ADHD)及過動症之疾病,以及發展性協調障礙(developmental coordination disorder),特別是癲癇症或其混合症狀。
本發明之奶製品(或含有該奶製品之組成結構),特別是乳脂肪,可進一步應用於治療及/或預防炎症,特別是來自慢性炎症群,如類風溼性關節炎、皮膚病、胃腸道疾病(腸炎、孔羅氏病)、過敏,特別是發生在幼兒者、肺炎、呼吸功能衰退及慢性肺疾病,及其混合症狀。
本發明之奶產品(或含有該奶產品之組成結構)可進一步應用於治療及/或預防心血管疾病及/或肝病變。
本發明之奶產品(或組成結構),特別是根據本發明所述用於治療及/或預防心血管疾病及/或炎症及/或神經系統疾病之乳脂肪,係藉由降低哺乳動物(包括人類)血液的動脈粥樣硬化率至少10%(較佳為至少20%左右,更佳為至少30%左右),及/或增加哺乳動物(包括人類)血液中之(長鍊)多元不飽和脂肪酸含量。
本發明亦有關於一種具有低膽固醇含量之反芻動物奶產品(具有低膽固醇含量之乳汁或其製品),特別是一種添加有ω 3脂肪酸之乳脂肪,最好來自含有α亞麻酸(ALA)、(EPA)、(DHA)之群組,(其中ω 3脂肪酸之添加量為0.5%到10%左右(ω 3重量:脂肪重量),6%左右較佳(例如:相
對於奶產品總重脂肪之重量為100%)。
本發明係有關於一種反芻動物奶產品(乳汁或其製品),特別是一種可添加ω 3脂肪酸之乳脂肪,係為具少量膽固醇之α亞麻酸(ALA),(係具有一定ALA(莫爾)比率之亞麻酸,其含量係介於0.2到1.5左右之間,介於1與1.5左右之間更好)。
本發明之另一目的係有關於經由攝取本發明之奶產品(或含有該奶產品之組成結構)增加哺乳動物(包括人類)血液(或血清)中長鍊多元不飽和(ω 3)脂肪酸之方法,特別是本發明之乳脂肪,最好使其取代未降低膽固醇含量之(反芻動物)乳脂肪(膽固醇含量係為280mg/100g脂肪左右)。
本發明之又一目的係有關於經由攝取本發明之奶產品(或含有該奶產品之組成結構)降低哺乳動物(包括人類)血液中三酸甘油脂含量之方法,特別是本發明之乳脂肪,最好使其取代未降低膽固醇含量之(反芻動物)乳脂肪(膽固醇含量係為280mg/100g脂肪左右)。
本發明之又一目的係有關於經由攝取本發明之奶產品(或含有該奶產品之組成結構),特別是本發明之乳脂肪,增加哺乳動物(包括人類)血液中HDL膽固醇至少15%左右(最好至少30%左右,更好至少50%左右)之方法,且最好增加哺乳動物(包括人類)血液中之非HDL膽固醇含量少於20%左右,最好少於10%。
因此,本發明方法中之食物攝取可降低哺乳動物血液之動脈粥狀硬化率至少10%左右,最好至少20%左右,更好至少30%左右。
本發明之再一目的係有關於經由攝取含有(添加)或取自乳脂肪(或本發明之奶產品)之飼料或食品組成,降低哺乳動物(包括人類)血液中之膽固醇含量之方法,該飼料或食品組成之油脂含量係介於3%(乳汁)到85%左右(奶油)之間,最好介於22%到50%左右之間,更好係介於35%左右到45%左右之間)(重量:重量;以總重計算)或20%(乳汁)與98%(奶油)之間(重量:重量;以淨重計算),及一低膽固醇含量之乳脂肪,取代未降低膽固醇含量之(反芻動物)乳脂肪(其膽固醇含量係為280mg/100g脂肪左右)。
如歐洲專利EP-387708 B1所述之方法,發明人以β環糊精處理,以降低牛奶之膽固醇含量。
更精確地說,含有278mg膽固醇/100g脂肪之5kg牛乳脂肪於55℃在30分鐘之內混和5kg的6%之β環糊精溶劑構成一「水中油」之乳劑。具有較低膽固醇含量之乳脂肪(25mg/100g)係經由連續離心分離過程,用水清洗,二次連續離心分離過程,及真空乾燥取得。
發明人處理56隻老鼠,以多種組成結構應用在人類之心血管模式,模擬人類之飲食(脂肪含量介於12.5%及22%(%淨重)),並且包含已處理或未處理之乳脂肪,及一典型之(無乳脂肪)組成結構。
比較餵食動物添加大量乳脂肪與餵食典型組成結構者,發明人發現,血液中持續增加膽固醇並且在血液中傾向增加三酸甘油脂。然而,動脈粥狀硬化率,HDL/非HDL膽固醇之比率僅輕微減少。
因此,發明人決定餵食動物(包括人類)富膽固醇之乳脂肪(或未處理者,例如每100g脂肪含280mg左右之膽固醇),得出結果心血管病風險及相關疾病惡化之血液參數。
發明人進一步觀察到,餵食富膽固醇之乳脂肪的老鼠肝臟較大,同時膽固醇及三酸甘油酯含量也較高,分別增加到6倍及2倍左右。
同時發明人測量餵食本發明之降低膽固醇的乳脂肪(25mg/100g)的老鼠相同的血液參數。
比較餵食富膽固醇之乳脂肪的老鼠,發明人測量到餵食本發明之降低膽固醇的乳脂肪的動物血液中膽固醇、三酸甘油酯及動脈粥狀硬化率持續降低,經由比較餵食動物一般乳脂肪(富膽固醇者)之後,發明人得出結論,藉由本發明之奶產品(降低膽固醇之乳脂肪)可改善心血管疾病風險及相關疾病之主要血液參數測量結果。
比較餵食典型組成結構的老鼠,餵食本發明之降低膽固醇之乳脂肪之動物其血液三酸甘油酯含量並未持續增加。
餵食降低膽固醇之乳脂肪的動物(而非餵典型組成結構),「壞的」(非HDL)膽固醇未增加,好的膽固醇(HDL)持續增加,特別是當組成結構在22%脂肪,模擬人類的食物,特別是歐洲、美國和日本的食物。
他們的肝指數類似餵食典型組成結構的老鼠,除了三酸甘油酯和磷酯含量之值較高之外。
在所有餵食本發明之降低膽固醇乳脂肪的動物,其動脈粥狀硬化率持續顯著降低。
因此發明人得出結論,所有餵食富飽和脂肪酸之食物,其血液參數及肝指數並未降低,某些甚至數值上升。
發明人進一步發現,測量餵食本發明降低膽固醇乳脂肪之動物,其EPA、DHA在血漿含量持續顯著增加。
進一步增加動物(含人類)血液中長鍊ω3脂肪酸含量,發明人推斷低膽固醇乳脂肪係一相當適用於營養補給品,健康食品組成,或一種具療效之藥用成份。
發明人得出結論,該降低膽固醇之乳脂肪係安全且可改善多項哺乳動物(包括人類)的血液指數。
發明人再餵食其他組老鼠添加以具有ω3脂肪酸的α亞麻酸(ALA)之飼料。
強烈增加血漿中α的亞麻酸含量,當比較其他實驗組時,發明人提出僅僅一種少量的降低血液中三酸甘油酯及膽固醇。
發明人進一步提出,添加具有ω3脂肪酸的α亞麻酸的乳脂肪,及降低膽固醇乳脂肪含量(添加ALA)促使大大降低血液膽固醇及三酸甘油酯含量,配合持續增加血漿中三種ω3脂肪酸(ALA,EPA,DHA)。
因此,即使人們憂慮,動物(包括人類)餵食以低膽固醇乳汁(乳脂肪)會增加血液及肝的三酸甘油酯值(且具有高度心血管疾病風險),這些比較數據清楚顯示增加值並不顯著也不持續,這種變應是不必要的,也不會轉化增加肝的大小。更重要的是,本發明降低的膽固醇乳脂肪,得到增加長鍊之ω3脂肪酸,諸如在哺乳動物血漿測到的EPA,DHA,該長鍊之ω3脂肪酸已知係可多方面改善身體健康。在以下非限制的例子將敘述更多細節。
因此本發明發展出一種組成結構,其中乳脂肪係分別由低膽固醇乳脂肪及/或增加低膽固醇之乳脂肪之組成結構所取代。
典型的組成結構係包含10%左右到22%左右的脂肪(重量:重量;以淨重計)及一降低膽固醇成份(含有10mg/100g左右脂肪總重及150mg/100g左右脂肪總重,最好包含介於30mg/100g左右與150mg/100g左右脂肪總重之間,更好者包含介於30mg/100g左右及90mg/100g左右脂肪總重之間。
或者,熟悉此技藝及/或消費者可藉由本發明之奶產品(含有本發明之降低膽固醇之乳脂肪)取代習用奶產品複製前述之組成結構(亦可藉由降低其他富膽固醇之食物如肉類之攝取)達成,(係包含降低本發明之膽固醇之乳脂肪)。
發明人將56隻老鼠分成8組。
第一組G1:老鼠餵食以冬季奶的脂肪。
第二組G2:老鼠餵食以抽除膽固醇(例如,低膽固醇乳脂肪)的冬季奶的脂肪。
第三組G3:老鼠餵食以春季奶的脂肪。
第四組G4:老鼠餵食以增加ALA的春季奶的脂肪。
第五組G5:老鼠餵食以大量增加ALA的春季奶的脂肪。
第六組G6:老鼠餵食以抽除膽固醇並增加ALA的春季奶的脂肪。
第七組G7:老鼠餵食以抽除膽固醇並大量增加ALA的春季奶的脂肪。
第八組G8:控制老鼠餵食以習用的飼料。
本發明人在乳脂肪中混合β環糊精。膽固醇含量將降低至90%左右。
老鼠餵食5週第一種組成結構,係具有12.5%的脂肪(如以下表1所示)。
表一:12.5%脂肪食物
五週以後經由心臟穿刺採集斷食動物的血液樣本。
之後,老鼠將餵食12週具有22%脂肪的組成結構(如以下表二所示)。
表二:22%脂肪食物
註:表一與表二,礦物質與維生素係以混和狀態供應。標準混和物提供每日礦物質與維生素建議之容許攝取量。LA表示亞麻酸(ω6脂肪酸)。
實驗進行十五週之後(餵食十週22%脂肪組成之後),藉由心臟穿刺術採集斷食動物之第二血液樣本。
實驗進行十七週之後(餵食十二週之22%脂肪組成之後),藉由心臟穿刺術採集恢復進食動物之第三血液樣本。
對動物進行解剖,以便分析其器官。
表三進一步顯示其血漿指數。
第五週之血液樣本
第十五週之血液樣本
第十七週之血液樣本
表三:三個時間點的血液參數
非HDL/HDL比率代表從非HDL膽固醇除以HDL膽固醇之值測出之動脈粥狀硬化率。高的脈粥狀硬化率代表罹患心血管疾病的風險增加。
除了總膽固醇、膽固醇及飽和脂肪酸攝取量,測出之血液脈粥狀硬化率係為預估心血管疾病風險之獨立量測。
表四:動物體重與肝指數
如表四所示,顯然可見攝取低膽固醇乳脂肪組成結構之實驗組(G2和G7)其肝臟重量及膽固醇含量接近控制組(G8)之量測值,或甚至優於比控制組G1、G3,在某些方面優於G8。
除此之外,發明人測量G1到G7所有老鼠的血漿之脂肪酸值。
表五說明餵食動物降低膽固醇的脂肪,將使得增加血漿中多元不飽和脂肪酸含量,係消耗以磷酯形式存在之脂肪酸
中之單一不飽和脂肪酸含量,及消耗以三酸甘油酯形式存在之脂肪酸中飽和及單一不飽和脂肪酸。
在組成結構中添加ALA將致使血漿中多元不飽和脂肪酸增加,但是EPA及DHA值並非以相對值增加,甚至無法增加比G2所示更大之值。
Claims (5)
- 一種降低膽固醇含量之奶產品,其添加了ω 3脂肪酸,其ω 3脂肪酸係選自含有α亞麻酸(ALA)、二十碳五烯酸(EPA)及十二碳六烯酸(DHA)之組成(其中ω 3脂肪酸與亞麻酸之(莫爾)比率係為0.2左右到1.5左右),其膽固醇含量係介於10mg/100g脂肪與150mg/100g脂肪之間,並包含60%到70%的飽和脂肪含量(飽和脂肪酸重量:總重),其係用於治療及/或預防心血管疾病及/或炎症疾病及/或肝病變及/或神經性疾病,係藉由增加哺乳動物血液中之長鍊多元不飽和脂肪酸含量。
- 如申請專利範圍第1項所述降低膽固醇含量之奶產品,其中該降低膽固醇含量之奶產品係包括乳汁、無水乳脂肪、塗抹料、冰淇淋、奶精、乳酪、發酵乳、加味乳及鮮奶油等其中之產品,其中該塗抹料為奶油或乳製品塗抹料。
- 如申請專利範圍第1項至第2項中任何一項所述降低膽固醇含量之奶產品係用於降低動脈粥狀硬化率。
- 如申請專利範圍第3項所述降低膽固醇含量之奶產品係用於治療及/或預防心血管疾病及/或炎症疾病及/或神經性疾病,係藉由降低哺乳動物(包括人類)血液之動脈粥狀硬化率到至少10%,及/或增加哺乳動物(包括人類)血液中之(長鍊)多元不飽和脂肪酸含量,其中增加哺乳動物(包括人類)血液中之(長鍊)多元不飽和脂肪酸含量係消耗以磷酯形式存在之脂肪酸中之單一不飽和脂 肪酸含量,及消耗以三酸甘油酯形式存在之脂肪酸中飽和及單一不飽和脂肪酸而達成。
- 如申請專利範圍第1項所述降低膽固醇含量之奶產品,其中ω 3脂肪酸與亞麻酸之(莫爾)比率係為1左右到1.5左右。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09158666 | 2009-04-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201039755A TW201039755A (en) | 2010-11-16 |
TWI589228B true TWI589228B (zh) | 2017-07-01 |
Family
ID=40672244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW099112408A TWI589228B (zh) | 2009-04-23 | 2010-04-20 | 降低膽固醇含量之奶產品 |
Country Status (25)
Country | Link |
---|---|
US (1) | US20120034308A1 (zh) |
EP (1) | EP2421380B1 (zh) |
JP (1) | JP5770716B2 (zh) |
KR (1) | KR20120007058A (zh) |
AR (1) | AR076399A1 (zh) |
AU (1) | AU2010240858B2 (zh) |
BR (1) | BRPI1006404B1 (zh) |
CA (1) | CA2753784C (zh) |
CY (1) | CY1119845T1 (zh) |
DK (1) | DK2421380T3 (zh) |
ES (1) | ES2648052T3 (zh) |
HR (1) | HRP20171747T1 (zh) |
HU (1) | HUE037345T2 (zh) |
LT (1) | LT2421380T (zh) |
MX (1) | MX356969B (zh) |
NO (1) | NO2421380T3 (zh) |
NZ (1) | NZ594821A (zh) |
PL (1) | PL2421380T3 (zh) |
PT (1) | PT2421380T (zh) |
RU (1) | RU2546283C2 (zh) |
SI (1) | SI2421380T1 (zh) |
TW (1) | TWI589228B (zh) |
UA (1) | UA109526C2 (zh) |
UY (1) | UY32576A (zh) |
WO (1) | WO2010122138A1 (zh) |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE862264R (fr) * | 1977-12-23 | 1978-06-23 | Nestle Sa | Procede de fabrication d'un produit alimentaire du genre beurre ou margarine |
US4996072A (en) * | 1987-03-02 | 1991-02-26 | General Mills, Inc. | Physical process for the deodorization and/or cholesterol reduction of fats and oils |
US4804555A (en) * | 1986-10-21 | 1989-02-14 | General Mills, Inc. | Physical process for simultaneous deodorization and cholesterol reduction of fats and oils |
US5092964A (en) * | 1989-02-03 | 1992-03-03 | Campbell Soup Company | Production of low cholesterol butter oil by vapor sparging |
BE1003488A3 (fr) * | 1989-03-14 | 1992-04-07 | Corman N Sa | Procede de reduction de la teneur en cholesterol et en acides gras libres de la matiere grasse d'origine animale et matiere grasse ainsi obtenue. |
US5340602A (en) * | 1989-04-20 | 1994-08-23 | Hermann Hoche | Process for the production of low cholesterol butterfat or butter |
ES2060687T3 (es) * | 1989-04-20 | 1994-12-01 | Hermann Hoche | Procedimiento para fabricar grasa animal baja en colesterina, en particular grasa de mantequilla o mantequilla; asi como instalacion para fabricarla. |
FR2648988B1 (fr) * | 1989-06-29 | 1991-10-18 | Roquette Freres | Procede de fabrication de produits laitiers a teneur reduite en sterols, et produits ainsi obtenus |
US5175015A (en) | 1990-01-30 | 1992-12-29 | Rich Products Corporation | Process of making low fat low cholesterol milk products |
JPH03229800A (ja) * | 1990-02-05 | 1991-10-11 | Snow Brand Milk Prod Co Ltd | コレステロール含量を低減した動物性油脂の製造方法 |
US5378487A (en) * | 1993-03-17 | 1995-01-03 | Kraft General Foods, Inc. | Oil extraction of cholesterol from milk products |
US6630192B2 (en) * | 1995-04-07 | 2003-10-07 | Brandeis University | Increasing the HDL level and the HDL/LDL ratio in human serum by balancing saturated and polyunsaturated dietary fatty acids |
WO1998020150A1 (fr) | 1996-11-07 | 1998-05-14 | Kyowa Hakko Kogyo Co., Ltd. | Procede de preparation d'un compose destine a baisser le taux de cholesterol |
US6303803B1 (en) * | 1997-01-31 | 2001-10-16 | Cargill, Incorporated | Removal of sterols from fats and oils |
US6110517A (en) * | 1997-08-02 | 2000-08-29 | Se Jong University | Method for removing cholesterol from milk and cream |
AU2002361461A1 (en) * | 2002-12-10 | 2004-06-30 | Rajeev Vijay Hiremath | Producing cholesterolfree meat, egg and milk |
WO2004064820A2 (en) | 2003-01-20 | 2004-08-05 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels |
US20040191294A1 (en) * | 2003-03-27 | 2004-09-30 | Ramaprasad Talahalli Ravichandra | Health composition |
KR100791978B1 (ko) * | 2005-06-21 | 2008-01-04 | 곽해수 | 콜레스테롤 제거용 베타-싸이클로덱스트린의 가교화 및그의 재생방법 |
DK1983989T3 (da) * | 2006-02-09 | 2013-10-14 | Ca Nat Research Council | Kombinationer af botaniske ekstrakter til fremme af kardiovaskulær sundhed |
WO2008081834A1 (ja) * | 2006-12-28 | 2008-07-10 | Ezaki Glico Co., Ltd. | グリコーゲンを含む食品とその用途 |
EP2055195A1 (fr) * | 2007-10-29 | 2009-05-06 | Corman S.A. | Procédé de reduction de la teneur en acides gras saturés de la matiere grasse du lait , produits obtenus et applications de ceux-ci. |
-
2010
- 2010-04-20 TW TW099112408A patent/TWI589228B/zh not_active IP Right Cessation
- 2010-04-23 HU HUE10721365A patent/HUE037345T2/hu unknown
- 2010-04-23 WO PCT/EP2010/055424 patent/WO2010122138A1/en active Application Filing
- 2010-04-23 CA CA2753784A patent/CA2753784C/en active Active
- 2010-04-23 BR BRPI1006404-4A patent/BRPI1006404B1/pt not_active IP Right Cessation
- 2010-04-23 AU AU2010240858A patent/AU2010240858B2/en not_active Ceased
- 2010-04-23 MX MX2011011128A patent/MX356969B/es active IP Right Grant
- 2010-04-23 AR ARP100101363A patent/AR076399A1/es active IP Right Grant
- 2010-04-23 ES ES10721365.4T patent/ES2648052T3/es active Active
- 2010-04-23 PT PT107213654T patent/PT2421380T/pt unknown
- 2010-04-23 JP JP2012506513A patent/JP5770716B2/ja not_active Expired - Fee Related
- 2010-04-23 RU RU2011138722/15A patent/RU2546283C2/ru active
- 2010-04-23 NZ NZ594821A patent/NZ594821A/en not_active IP Right Cessation
- 2010-04-23 UY UY0001032576A patent/UY32576A/es not_active Application Discontinuation
- 2010-04-23 SI SI201031583T patent/SI2421380T1/en unknown
- 2010-04-23 KR KR1020117027829A patent/KR20120007058A/ko active Search and Examination
- 2010-04-23 DK DK10721365.4T patent/DK2421380T3/en active
- 2010-04-23 PL PL10721365T patent/PL2421380T3/pl unknown
- 2010-04-23 US US13/262,606 patent/US20120034308A1/en not_active Abandoned
- 2010-04-23 NO NO10721365A patent/NO2421380T3/no unknown
- 2010-04-23 UA UAA201111173A patent/UA109526C2/ru unknown
- 2010-04-23 LT LTEP10721365.4T patent/LT2421380T/lt unknown
- 2010-04-23 EP EP10721365.4A patent/EP2421380B1/en active Active
-
2017
- 2017-11-13 HR HRP20171747TT patent/HRP20171747T1/hr unknown
- 2017-11-22 CY CY20171101217T patent/CY1119845T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR20120007058A (ko) | 2012-01-19 |
RU2546283C2 (ru) | 2015-04-10 |
CA2753784A1 (en) | 2010-10-28 |
MX2011011128A (es) | 2011-11-18 |
BRPI1006404A2 (pt) | 2015-08-25 |
BRPI1006404B1 (pt) | 2018-05-29 |
US20120034308A1 (en) | 2012-02-09 |
NZ594821A (en) | 2014-05-30 |
HRP20171747T1 (hr) | 2017-12-29 |
AU2010240858A1 (en) | 2011-09-15 |
WO2010122138A1 (en) | 2010-10-28 |
HUE037345T2 (hu) | 2018-08-28 |
CY1119845T1 (el) | 2018-06-27 |
JP2012524533A (ja) | 2012-10-18 |
TW201039755A (en) | 2010-11-16 |
AR076399A1 (es) | 2011-06-08 |
UY32576A (es) | 2010-11-30 |
RU2011138722A (ru) | 2013-05-27 |
AU2010240858B2 (en) | 2015-05-28 |
CA2753784C (en) | 2017-09-05 |
MX356969B (es) | 2018-06-21 |
EP2421380B1 (en) | 2017-08-23 |
PL2421380T3 (pl) | 2018-02-28 |
ES2648052T3 (es) | 2017-12-28 |
JP5770716B2 (ja) | 2015-08-26 |
UA109526C2 (uk) | 2015-09-10 |
NO2421380T3 (zh) | 2018-01-20 |
DK2421380T3 (en) | 2017-12-04 |
SI2421380T1 (en) | 2018-01-31 |
LT2421380T (lt) | 2017-12-11 |
EP2421380A1 (en) | 2012-02-29 |
CN102413703A (zh) | 2012-04-11 |
PT2421380T (pt) | 2017-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Haug et al. | Bovine milk in human nutrition–a review | |
Tunick et al. | Dairy products and health: recent insights | |
Lima et al. | Nutritional and health profile of goat products: focus on health benefits of goat milk | |
JP5079805B2 (ja) | 極性脂質強化乳成分およびその適用 | |
EP2173184A1 (en) | Omega-3 fatty acid fortified composition | |
dos Santos et al. | Goat milk as a natural source of bioactive compounds and strategies to enhance the amount of these beneficial components | |
Pfeuffer et al. | Nutrition and health aspects of milk and dairy products and their ingredients | |
Park | Goat milk and human nutrition | |
JP3581010B2 (ja) | 脂質の消化吸収機能改善剤 | |
JP3891536B2 (ja) | 哺乳動物の乳由来のリン脂質含有経口性組成物 | |
EP2037757B1 (en) | Feed product for dairy cows and method of obtaining a dairy product | |
TWI589228B (zh) | 降低膽固醇含量之奶產品 | |
Issara et al. | Instant organic rice bran milk: A nutritional quality aspect. | |
Pandya et al. | Overview of functionality of goat and sheep milk | |
Ali et al. | The effect of partially or totally replacing milk fat by jojoba oil in Domiati cheese production on some nutritional and quality properties | |
JP2006022068A (ja) | 血清脂質代謝改善剤 | |
Galli et al. | The role of fats in milk and dairy products in nutrition and health from infancy to adulthood | |
Hazra et al. | Ghee as medicine | |
JP2009269864A (ja) | リン脂質結合型アラキドン酸増加剤 | |
Abbas et al. | MILK BIOACTIVE LIPIDS AS POTENTIAL HEALTHY FRACTIONS: A REVIEW | |
Gohri et al. | Charu Bharti and Garima Sahu | |
CN102413703B (zh) | 用作药物的低胆固醇乳制品 | |
WO2005036981A1 (en) | Method for enriching nervonic acid in expressed milk of ruminants | |
JP2022533921A (ja) | 食品用ブチレート及びその使用 | |
JP2013181024A (ja) | 脂肪酸組成改良剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |